Prosecution Insights
Prosecution Insights
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (12%) |
| §103 only | 1 (12%) |
| §102 only | 1 (12%) |
| §112 only | 1 (12%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 44.4% | +29.3% |
| QIAN, CELINE X | 1 | 47.6% | +16.6% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.8% | +19.6% |
| AMICK, THOMAS RUSSE | 1 | 72.6% | +31.1% |
| YU, MISOOK | 1 | 39.1% | +17.2% |
| BRISTOL, LYNN ANNE | 1 | 63.5% | +39.8% |
| GODDARD, LAURA B | 1 | 50.9% | +14.1% |
| MIANO, JOSEPH PAUL | 1 | 36.1% | +64.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17693060 | ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF | YU, MISOOK | 176d overdue |
| 18155115 | METHODS OF TREATING LEPTOMENINGEAL METASTASIS | WHITE, DAWANNA SHAR-DAY | 28d |
| 18535012 | ANTI-UPAR ANTIBODIES AND USES THEREOF | NICKOL, GARY B | — |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | — |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | AMICK, THOMAS RUSSE | — |
| 17692979 | ANTI-CD371 ANTIBODIES AND USES THEREOF | BRISTOL, LYNN ANNE | — |
| 17590585 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF | GODDARD, LAURA B | — |
| 17578989 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY | MIANO, JOSEPH PAUL | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1627 | 1 |
| 1638 | 1 |
| 1641 | 1 |
| 1643 | 1 |
| 1600 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18535012 | ANTI-UPAR ANTIBODIES AND USES THEREOF | NICKOL, GARY B | — | §112DP | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18306890 | CELLS WITH CD70 KNOCKOUT AND USES FOR IMMUNOTHERAPY | QIAN, CELINE X | 1637 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 25, 2023 |
| 18155115 | METHODS OF TREATING LEPTOMENINGEAL METASTASIS | WHITE, DAWANNA SHAR-DAY | 1627 | §103Other | Non-Final OA | 28d | Pending | Jan 17, 2023 |
| 17831638 | CELLS EXPRESSING C-KIT MUTATIONS AND USES THEREOF | AMICK, THOMAS RUSSE | 1638 | §112 | Non-Final OA | — | Pending | Jun 03, 2022 |
| 17693060 | ANTIGEN RECOGNIZING RECEPTORS TARGETING CD371 AND USES THEREOF | YU, MISOOK | 1641 | DP | Final Rejection | 176d overdue | Pending | Mar 11, 2022 |
| 17692979 | ANTI-CD371 ANTIBODIES AND USES THEREOF | BRISTOL, LYNN ANNE | 1643 | DPOther | Non-Final OA | — | Pending | Mar 11, 2022 |
| 17590585 | CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF | GODDARD, LAURA B | 1600 | §102 | Final Rejection | — | Pending | Feb 01, 2022 |
| 17578989 | FUSION POLYPEPTIDE FOR IMMUNOTHERAPY | MIANO, JOSEPH PAUL | 1631 | §102§103§112DP | Final Rejection | — | Pending | Jan 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial